Phase 3 underway
Evidence outlook · registrational
Colorectal Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. No registrational readout date is posted for this indication; a Phase 3 is registered in Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors (NCT06279130); see the registry list.
Also in development: Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Non-Small Cell Lung Cancer · investigational · Featured evidence · 2 Gastric Cancer · not a covered market · Outside covered markets · 1 investigational Featured evidence · 2
Competitive landscape 67 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 64 same-indication; 59 further along in development.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Botensilimab: this drug Phase 3 Monoclonal antibody CTLA-4 Tremelimumab Approved Monoclonal antibody CTLA-4 Gotistobart Phase 3 Monoclonal antibody CTLA-4 BA3071 Phase 1/2 Biologic (subtype unspecified) CTLA-4 Afatinib (Gilotrif)Approved Small molecule EGFR/HER1, HER2, HER4 Alectinib (Alecensa)Approved Small molecule ALK Alymsys (bevacizumab-Maly) Approved Monoclonal antibody VEGF-A Amivantamab Approved Multispecific antibody EGFR x c-MET Atezolizumab Approved Monoclonal antibody PD-L1 BAT1706 (Avzivi)Approved Monoclonal antibody VEGF-A BAY2927088 (Hyrnuo)Approved Small molecule HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR Bevacizumab Approved Monoclonal antibody VEGF-A , Vascular Endothelial Growth Factor Inhibitor Bevacizumab-Awwb (MVASI)Approved Monoclonal antibody VEGF-A Binimetinib Approved Small molecule MEK1/2 Brigatinib Approved Small molecule ALK Capmatinib Approved Small molecule MET
…and 52 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (27 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1) December 2026 (1) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2026-12 ·
NCT06300463 ·
CT.gov ↗ What to watch 2027 (11) January 2027 (3) Phase 1 Colorectal Cancer Recruiting
Est. primary completion 2027-01-01 ·
NCT07128355 ·
CT.gov ↗ What to watch Phase 2 Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma Recruiting
Est. primary completion 2027-01-01 ·
NCT07735624 ·
CT.gov ↗ What to watch Phase 1 Colorectal Cancer Recruiting
Est. primary completion 2027-01-15 ·
NCT06336902 ·
CT.gov ↗ What to watch April 2027 (1) Phase 2 Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma Active not recruiting
Est. primary completion 2027-04-07 ·
NCT04028063 ·
CT.gov ↗ What to watch May 2027 (2) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2027-05 ·
NCT05845450 ·
CT.gov ↗ What to watch Phase 2 Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon Cancer AJCC v8 … Recruiting
Est. primary completion 2027-05-27 ·
NCT07595874 ·
CT.gov ↗ What to watch June 2027 (1) Phase 1/2 Colorectal Cancer Active not recruiting
Est. primary completion 2027-06-16 ·
NCT05627635 ·
CT.gov ↗ What to watch July 2027 (1) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2027-07-31 ·
NCT06589440 ·
CT.gov ↗ What to watch August 2027 (1) Phase 2 Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer … Active not recruiting
Est. primary completion 2027-08-01 ·
NCT06251973 ·
CT.gov ↗ What to watch September 2027 (1) Phase 2 Colorectal Cancer Active not recruiting
Est. primary completion 2027-09 ·
NCT05608044 ·
CT.gov ↗ What to watch November 2027 (1) Phase 2 Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8 Recruiting
Est. primary completion 2027-11-05 ·
NCT06780787 ·
CT.gov ↗ What to watch 2028 (7) February 2028 (2) Phase 2 Advanced Melanoma Active not recruiting
Est. primary completion 2028-02 ·
NCT05529316 ·
CT.gov ↗ What to watch Phase 2 Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma Recruiting
Est. primary completion 2028-02-20 ·
NCT06843434 ·
CT.gov ↗ What to watch April 2028 (1) Phase 1 Colorectal Cancer Recruiting
Est. primary completion 2028-04-15 ·
NCT07193862 ·
CT.gov ↗ What to watch May 2028 (1) Phase 3 Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer Recruiting
Est. primary completion 2028-05-15 ·
NCT06346197 ·
CT.gov ↗ What to watch July 2028 (1) Phase 2 Colorectal Cancer Active not recruiting
Est. primary completion 2028-07 ·
NCT06268015 ·
CT.gov ↗ What to watch September 2028 (1) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2028-09 ·
NCT07550088 ·
CT.gov ↗ What to watch December 2028 (1) Phase 2 Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Recruiting
Est. primary completion 2028-12-31 ·
NCT07516366 ·
CT.gov ↗ What to watch 2029 (4) January 2029 (1) Phase 2/3 Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors Recruiting
Est. primary completion 2029-01-29 ·
NCT06279130 ·
CT.gov ↗ What to watch February 2029 (1) Phase 2 Untreated, Advanced Pancreatic Cancer Not yet recruiting
Est. primary completion 2029-02-28 ·
NCT07578337 ·
CT.gov ↗ What to watch August 2029 (1) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2029-08-28 ·
NCT07551596 ·
CT.gov ↗ What to watch November 2029 (1) Phase 1 Colorectal Cancer Recruiting
Est. primary completion 2029-11-01 ·
NCT06411691 ·
CT.gov ↗ What to watch 2030 (3) April 2030 (1) Phase 2 Non-Small Cell Lung Cancer Active not recruiting
Est. primary completion 2030-04 ·
NCT06322108 ·
CT.gov ↗ What to watch August 2030 (1) Phase 2 Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer Recruiting
Est. primary completion 2030-08-01 ·
NCT06843551 ·
CT.gov ↗ What to watch November 2030 (1) Phase 2 Colorectal Cancer Recruiting
Est. primary completion 2030-11 ·
NCT07227636 ·
CT.gov ↗ What to watch 2031 (1) July 2031 (1) Phase 2 Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme Active not recruiting
Est. primary completion 2031-07-31 ·
NCT05864534 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (38) Colorectal Cancer (19) Non-Small Cell Lung Cancer (2) Other / comorbidity (18)
Phase 3 (2) Phase 2/3 (1) Phase 2 (25) Phase 1/2 (2) Phase 1 (8)